Mice lacking dystrophin or α sarcoglycan spontaneously develop embryonal rhabdomyosarcoma with cancer-associated p53 mutations and alternatively spliced or mutant Mdm2 transcripts

American Journal of Pathology

Volumn 176, Issue 1, 2010, Pages 416-434

  Fernandez, Karen ^a   Serinagaoglu, Yelda ^a   Hammond, Sue ^a,b   Martin, Laura T ^a,b   Martin, Paul T ^a,b  

^a NATIONWIDE CHILDREN S HOSPITAL   (United States)

^b THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA DYSTROGLYCAN; ALPHA SARCOGLYCAN; DYSTROPHIN; MESSENGER RNA; MUTANT PROTEIN; PHOSPHATASE; PROTEIN KINASE B; PROTEIN MDM2; PROTEIN P53; RETINOBLASTOMA PROTEIN; SOMATOMEDIN B;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; GENE EXPRESSION; GENE MUTATION; GLYCOSYLATION; KNOCKOUT MOUSE; MISSENSE MUTATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; RHABDOMYOSARCOMA; X CHROMOSOME LINKED MUSCULAR DYSTROPHIC MOUSE;

EID: 73949088241     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.2353/ajpath.2010.090405     Document Type: Article

References (104)

1. Durbeej M, Henry MD, Campbell KP: Dystroglycan in development and disease. Curr Opin Cell Biol 1998, 10:594-601
2. Henry MD, Campbell KP: Dystroglycan: an extracellular matrix receptor linked to the cytoskeleton. Curr Opin Cell Biol 1996, 8:625-631
3. Barresi R, Campbell KP: Dystroglycan: from biosynthesis to pathogenesis of human disease. J Cell Sci 2006, 119:199-207
4. Sgambato A, Brancaccio A: The dystroglycan complex: from biology to cancer. J Cell Physiol 2005, 205:163-169
5. Brennan PA, Jing J, Ethunandan M, Gorecki D: Dystroglycan complex in cancer. Eur J Surg Oncol 2004, 30:589-592
6. Parham DM, Ellison DA: Rhabdomyosarcomas in adults and children: an update. Arch Pathol Lab Med 2006, 130:1454-1465
7. Blake DJ, Weir A, Newey SE, Davies KE: Function and genetics of dystrophin and dystrophin-related proteins in muscle. Physiol Rev 2002, 82:291-329
8. Ervasti JM, Campbell KP: Membrane organization of the dystrophinglycoprotein complex. Cell 1991, 66:1121-1131
9. Ibraghimov-Beskrovnaya O, Ervasti JM, Leveille CJ, Slaughter CA, Sernett SW, Campbell KP: Primary structure of dystrophin-associated glycoproteins linking dystrophin to the extracellular matrix. Nature 1992, 355:696-702
10. Chung W, Campanelli JT: WW and EF hand domains of dystrophinfamily proteins mediate dystroglycan binding. Mol Cell Biol Res Commun 1999, 2:162-171
11. Rezniczek GA, Konieczny P, Nikolic B, Reipert S, Schneller D, Abrahamsberg C, Davies KE, Winder SJ, Wiche G: Plectin 1f scaffolding at the sarcolemma of dystrophic (mdx) muscle fibers through multiple interactions with beta-dystroglycan. J Cell Biol 2007, 176: 965-977
12. Yang B, Jung D, Motto D, Meyer J, Koretzky G, Campbell KP: SH3 domain-mediated interaction of dystroglycan and Grb2. J Biol Chem 1995, 270:11711-11714
13. Zhan Y, Tremblay MR, Melian N, Carbonetto S: Evidence that dystroglycan is associated with dynamin and regulates endocytosis. J Biol Chem 2005, 280:18015-18024
14. Spence HJ, Dhillon AS, James M, Winder SJ: Dystroglycan, a scaffold for the ERK-MAP kinase cascade. EMBO Rep 2004, 5:484-489
15. Langenbach KJ, Rando TA: Inhibition of dystroglycan binding to laminin disrupts the PI3K/AKT pathway and survival signaling in muscle cells. Muscle Nerve 2002, 26:644-653
16. Sotgia F, Lee H, Bedford MT, Petrucci T, Sudol M, Lisanti MP: Tyrosine phosphorylation of beta-dystroglycan at its WW domain binding motif. PPxY, recruits SH2 domain containing proteins. Biochemistry 2001, 40:14585-14592
17. Apel ED, Roberds SL, Campbell KP, Merlie JP: Rapsyn may function as a link between the acetylcholine receptor and the agrin-binding dystrophin-associated glycoprotein complex. Neuron 1995, 15:115-126
18. Ervasti JM, Campbell KP: A role for the dystrophin-glycoprotein complex as a transmembrane linker between laminin and actin. J Cell Biol 1993, 122:809-823
19. Michele DE, Campbell KP: Dystrophin-glycoprotein complex: posttranslational processing and dystroglycan function. J Biol Chem 2003, 278:15457-15460
20. Hoffman EP, Brown RH Jr, Kunkel LM: Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 1987, 51:919-928
21. Sunada Y, Bernier SM, Kozak CA, Yamada Y, Campbell KP: Deficiency of merosin in dystrophic dy mice and genetic linkage of lamininMchain gene to dy locus. J Biol Chem 1994, 269:13729-13732
22. Xu H, Christmas P, Wu XR, Wewer UM, Engvall E: Defective muscle basement membrane and lack of M-laminin in the dystrophic dy/dy mouse. Proc Natl Acad Sci USA 1994, 91:5572-5576
23. Sicinski P, Geng Y, Ryder-Cook AS, Barnard EA, Darlison MG, Barnard PJ: The molecular basis of muscular dystrophy in the mdx mouse: a point mutation. Science 1989, 244:1578-1580
24. Vainzof M, Passos-Bueno MR, Canovas M, Moreira ES, Pavanello RC, Marie SK, Anderson LV, Bonnemann CG, McNally EM, Nigro V, Kunkel LM, Zatz M: The sarcoglycan complex in the six autosomal recessive limb-girdle muscular dystrophies. Hum Mol Genet 1996, 5:1963-1969
25. Martin PT: Mechanisms of Disease: congenital muscular dystrophies-glycosylation takes center stage. Nat Clin Pract Neurol 2006, 2:222-230
26. Losasso C, Di Tommaso F, Sgambato A, Ardito R, Cittadini A, Giardina B, Petrucci TC, Brancaccio A: Anomalous dystroglycan in carcinoma cell lines. FEBS Lett 2000, 484:194-198
27. Henry MD, Cohen MB, Campbell KP: Reduced expression of dystroglycan in breast and prostate cancer. Hum Pathol 2001, 32:791-795
28. Muschler J, Levy D, Boudreau R, Henry M, Campbell K, Bissell MJ: A role for dystroglycan in epithelial polarization: loss of function in breast tumor cells. Cancer Res 2002, 62:7102-7109
29. Sgambato A, Migaldi M, Montanari M, Camerini A, Brancaccio A, Rossi G, Cangiano R, Losasso C, Capelli G, Trentini GP, Cittadini A: Dystroglycan expression is frequently reduced in human breast and colon cancers and is associated with tumor progression. Am J Pathol 2003, 162:849-860
30. Jing J, Lien CF, Sharma S, Rice J, Brennan PA, Gorecki DC: Aberrant expression, processing and degradation of dystroglycan in squamous cell carcinomas. Eur J Cancer 2004, 40:2143-2151
31. Calogero A, Pavoni E, Gramaglia T, D'Amati G, Ragona G, Brancaccio A, Petrucci TC: Altered expression of alpha-dystroglycan subunit in human gliomas. Cancer Biol Ther 2006, 5:441-448
32. Martin LT, Glass M, Dosunmu E, Martin PT: Altered expression of natively glycosylated alpha dystroglycan in pediatric solid tumors. Hum Pathol 2007, 38:1657-1668
33. Beltran-Valero de Bernabe D, Inamori KI, Yoshida-Moriguchi T, Weydert CJ, Harper HA, Willer T, Henry MD, Campbell KP: Loss of alphadystroglycan laminin binding in epithelium-derived cancers is caused by silencing of large. J Biol Chem 2009, 285:11279-11284
34. Sgambato A, Di Salvatore MA, De Paola B, Rettino A, Faraglia B, Boninsegna A, Graziani C, Camerini A, Proietti G, Cittadini A: Analysis of dystroglycan regulation and functions in mouse mammary epithelial cells and implications for mammary tumorigenesis. J Cell Physiol 2006, 207:520-529
35. Singh J, Itahana Y, Knight-Krajewski S, Kanagawa M, Campbell KP, Bissell MJ, Muschler J: Proteolytic enzymes and altered glycosylation modulate dystroglycan function in carcinoma cells. Cancer Res 2004, 64:6152-6159
36. Matsumura K, Ervasti JM, Ohlendieck K, Kahl SD, Campbell KP: Association of dystrophin-related protein with dystrophin-associated proteins in mdx mouse muscle. Nature 1992, 360:588-591
37. Duclos F, Straub V, Moore SA, Venzke DP, Hrstka RF, Crosbie RH, Durbeej M, Lebakken CS, Ettinger AJ, van der Meulen J, Holt KH, Lim LE, Sanes JR, Davidson BL, Faulkner JA, Williamson R, Campbell KP: Progressive muscular dystrophy in alpha-sarcoglycan-deficient mice. J Cell Biol 1998, 142:1461-1471
38. Arndt CA, Crist WM: Common musculoskeletal tumors of childhood and adolescence. N Engl J Med 1999, 341:342-352
39. Morotti RA, Nicol KK, Parham DM, Teot LA, Moore J, Hayes J, Meyer W, Qualman SJ: An immunohistochemical algorithm to facilitate diagnosis and subtyping of rhabdomyosarcoma: the Children's Oncology Group experience. Am J Surg Pathol 2006, 30:962-968
40. Parham DM: Pathologic classification of rhabdomyosarcomas and correlations with molecular studies. Mod Pathol 2001, 14:506-514
41. Davis RJ, D'Cruz CM, Lovell MA, Biegel JA, Barr FG: Fusion of PAX7 to FKHR by the variant t(1;13)(p36;q14) translocation in alveolar rhabdomyosarcoma. Cancer Res 1994, 54:2869-2872
42. Barr FG, Galili N, Holick J, Biegel JA, Rovera G, Emanuel BS: Rearrangement of the PAX3 paired box gene in the paediatric solid tumour alveolar rhabdomyosarcoma. Nat Genet 1993, 3:113-117
43. Barr FG: Gene fusions involving PAX and FOX family members in alveolar rhabdomyosarcoma. Oncogene 2001, 20:5736-5746
44. Koufos A, Hansen MF, Copeland NG, Jenkins NA, Lampkin BC, Cavenee WK: Loss of heterozygosity in three embryonal tumours suggests a common pathogenetic mechanism. Nature 1985, 316:330-334
45. Anderson J, Gordon A, McManus A, Shipley J, Pritchard-Jones K: Disruption of imprinted genes at chromosome region 11p15.5 in paediatric rhabdomyosarcoma. Neoplasia 1999, 1:340-348
46. Sorensen PH, Lynch JC, Qualman SJ, Tirabosco R, Lim JF, Maurer HM, Bridge JA, Crist WM, Triche TJ, Barr FG: PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the children's oncology group. J Clin Oncol 2002, 20:2672-2679
47. Li FP, Fraumeni JF Jr: Rhabdomyosarcoma in children: epidemiologic study and identification of a familial cancer syndrome. J Natl Cancer Inst 1969, 43:1365-1373
48. Anderson J, Gordon A, Pritchard-Jones K, Shipley J: Genes, chromosomes, and rhabdomyosarcoma. Genes Chromosomes Cancer 1999, 26:275-285
49. Taylor AC, Shu L, Danks MK, Poquette CA, Shetty S, Thayer MJ, Houghton PJ, Harris LC: P53 mutation and MDM2 amplification frequency in pediatric rhabdomyosarcoma tumors and cell lines. Med Pediatr Oncol 2000, 35:96-103
50. Felix CA, Kappel CC, Mitsudomi T, Nau MM, Tsokos M, Crouch GD, Nisen PD, Winick NJ, Helman LJ: Frequency and diversity of p53 mutations in childhood rhabdomyosarcoma. Cancer Res 1992, 52:2243-2247
51. Takahashi Y, Oda Y, Kawaguchi K, Tamiya S, Yamamoto H, Suita S, Tsuneyoshi M: Altered expression and molecular abnormalities of cell-cycle-regulatory proteins in rhabdomyosarcoma. Mod Pathol 2004, 17:660-669
52. Keller C, Arenkiel BR, Coffin CM, El-Bardeesy N, DePinho RA, Capecchi MR: Alveolar rhabdomyosarcomas in conditional Pax3: Fkhr mice: cooperativity of Ink4a/ARF and Trp53 loss of function. Genes Dev 2004, 18:2614-2626
53. Naini S, Etheridge KT, Adam SJ, Qualman SJ, Bentley RC, Counter CM, Linardic CM: Defining the cooperative genetic changes that temporally drive alveolar rhabdomyosarcoma. Cancer Res 2008, 68:9583-9588
54. Sharp R, Recio JA, Jhappan C, Otsuka T, Liu S, Yu Y, Liu W, Anver M, Navid F, Helman LJ, DePinho RA, Merlino G: Synergism between INK4a/ARF inactivation and aberrant HGF/SF signaling in rhabdomyosarcomagenesis. Nat Med 2002, 8:1276-1280
55. Iolascon A, Faienza MF, Coppola B, Rosolen A, Basso G, Della Ragione F, Schettini F: Analysis of cyclin-dependent kinase inhibitor genes (CDKN2A. CDKN2B, and CDKN2C) in childhood rhabdomyosarcoma, Genes Chromosomes Cancer 1996, 15:217-222
56. Cen L, Hsieh FC, Lin HJ, Chen CS, Qualman SJ, Lin J: PDK-1/AKT pathway as a novel therapeutic target in rhabdomyosarcoma cells using OSU-03012 compound. Br J Cancer 2007, 97:785-791
57. Tomita Y, Morooka T, Hoshida Y, Zhang B, Qiu Y, Nakamichi I, Hamada K, Ueda T, Naka N, Kudawara I, Aozasa K: Prognostic significance of activated AKT expression in soft-tissue sarcoma. Clin Cancer Res 2006, 12:3070-3077
58. Wan X, Helman LJ: Levels of PTEN protein modulate Akt phosphorylation on serine 473, but not on threonine 308, in IGF-II-overexpressing rhabdomyosarcomas cells. Oncogene 2003, 22:8205-8211
59. Li HG, Wang Q, Li HM, Kumar S, Parker C, Slevin M, Kumar P: PAX3 and PAX3-FKHR promote rhabdomyosarcoma cell survival through downregulation of PTEN. Cancer Lett 2007, 253:215-223
60. Fangusaro JR, Caldas H, Jiang Y, Altura RA: Survivin: an inhibitor of apoptosis in pediatric cancer. Pediatr Blood Cancer 2006, 47:4-13
61. Caldas H, Holloway MP, Hall BM, Qualman SJ, Altura RA: Survivindirected RNA interference cocktail is a potent suppressor of tumour growth in vivo. J Med Genet 2006, 43:119-128
62. Linardic CM, Counter CM: Genetic modeling of Ras-induced human rhabdomyosarcoma. Methods Enzymol 2008, 438:419-427
63. Eichenmuller M, Bauer R, Von Schweinitz D, Hahn H, Kappler R: Hedgehog-independent overexpression of transforming growth factor-beta1 in rhabdomyosarcoma of Patched1 mutant mice. Int J Oncol 2007, 31:405-412
64. Lee Y, Kawagoe R, Sasai K, Li Y, Russell HR, Curran T, McKinnon PJ: Loss of suppressor-of-fused function promotes tumorigenesis. Oncogene 2007, 26:6442-6447
65. Calzada-Wack J, Schnitzbauer U, Walch A, Wurster KH, Kappler R, Nathrath M, Hahn H: Analysis of the PTCH coding region in human rhabdomyosarcoma. Hum Mutat 2002, 20:233-234
66. Chen CL, Loy A, Cen L, Chan C, Hsieh FC, Cheng G, Wu B, Qualman SJ, Kunisada K, Yamauchi-Takihara K, Lin J: Signal transducer and activator of transcription 3 is involved in cell growth and survival of human rhabdomyosarcoma and osteosarcoma cells. BMC Cancer 2007, 7:111
67. Yang P, Grufferman S, Khoury MJ, Schwartz AG, Kowalski J, Ruymann FB, Maurer HM: Association of childhood rhabdomyosarcoma with neurofibromatosis type I and birth defects. Genet Epidemiol 1995, 12:467-474
68. Taniguchi E, Nishijo K, McCleish AT, Michalek JE, Grayson MH, Infante AJ, Abboud HE, Legallo RD, Qualman SJ, Rubin BP, Keller C: PDGFR-A is a therapeutic target in alveolar rhabdomyosarcoma. Oncogene 2008, 27:6550-6560
69. Wysoczynski M, Miekus K, Jankowski K, Wanzeck J, Bertolone S, Janowska-Wieczorek A, Ratajczak J, Ratajczak MZ: Leukemia inhibitory factor: a newly identified metastatic factor in rhabdomyosarcomas. Cancer Res 2007, 67:2131-2140
70. Keller C, Hansen MS, Coffin CM, Capecchi MR: Pax3:Fkhr interferes with embryonic Pax3 and Pax7 function: implications for alveolar rhabdomyosarcoma cell of origin. Genes Dev 2004, 18:2608-2613
71. Makawita S, Ho M, Durbin AD, Thorner PS, Malkin D, Somers GR: Expression of insulin-like growth factor pathway proteins in rhabdomyosarcoma: IGF-2 expression is associated with translocation-negative tumors. Pediatr Dev Pathol 2008, 12:127-135
72. Zhan S, Shapiro DN, Helman LJ: Activation of an imprinted allele of the insulin-like growth factor II gene implicated in rhabdomyosarcoma. J Clin Invest 1994, 94:445-448
73. Xu R, Chandrasekharan K, Yoon JH, Camboni M, Martin PT: Overexpression of the cytotoxic T cell (CT) carbohydrate inhibits muscular dystrophy in the dyW mouse model of congenital muscular dystrophy 1A. Am J Pathol 2007, 171:181-199
74. Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2 - delta delta C(T) method. Methods 2001, 25:402-408
75. Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, Hainaut P, Olivier M: Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat 2007, 28:622-629
76. Smith PL, Lowe JB: Molecular cloning of a murine N-acetylgalactosamine transferase cDNA that determines expression of the T lymphocyte-specific CT oligosaccharide differentiation antigen. J Biol Chem 1994, 269:15162-15171
77. Sheikh KA, Sun J, Liu Y, Kawai H, Crawford TO, Proia RL, Griffin JW, Schnaar RL: Mice lacking complex gangliosides develop Wallerian degeneration and myelination defects. Proc Natl Acad Sci USA 1999, 96:7532-7537
78. Takamiya K, Yamamoto A, Furukawa K, Yamashiro S, Shin M, Okada M, Fukumoto S, Haraguchi M, Takeda N, Fujimura K, Sakae M, Kishikawa M, Shiku H, Aizawa S: Mice with disrupted GM2/GD2 synthase gene lack complex gangliosides but exhibit only subtle defects in their nervous system. Proc Natl Acad Sci USA 1996, 93:10662-10667
79. Hedlund M, Tangvoranuntakul P, Takematsu H, Long JM, Housley GD, Kozutsumi Y, Suzuki A, Wynshaw-Boris A, Ryan AF, Gallo RL, Varki N, Varki A: N-glycolylneuraminic acid deficiency in mice: implications for human biology and evolution. Mol Cell Biol 2007, 27:4340-4346
80. De la Porte S, Morin S, Koenig J: Characteristics of skeletal muscle in mdx mutant mice. Int Rev Cytol 1999, 191:99-148
81. Seale P, Sabourin LA, Girgis-Gabardo A, Mansouri A, Gruss P, Rudnicki MA: Pax7 is required for the specification of myogenic satellite cells. Cell 2000, 102:777-786
82. Hara MR, Snyder SH: Nitric oxide-GAPDH-Siah: a novel cell death cascade. Cell Mol Neurobiol 2006, 26:527-538
83. Levine AJ: p53, the cellular gatekeeper for growth and division. Cell 1997, 88:323-331
84. Bartel F, Taubert H, Harris LC: Alternative and aberrant splicing of MDM2 mRNA in human cancer. Cancer Cell 2002, 2:9-15
85. Fridman JS, Hernando E, Hemann MT, de Stanchina E, Cordon-Cardo C, Lowe SW: Tumor promotion by Mdm2 splice variants unable to bind p53. Cancer Res 2003, 63:5703-5706
86. Leschziner A, Moukhles H, Lindenbaum M, Gee SH, Butterworth J, Campbell KP, Carbonetto S: Neural regulation of alpha-dystroglycan biosynthesis and glycosylation in skeletal muscle. J Neurochem 2000, 74:70-80
87. Acharyya S, Butchbach ME, Sahenk Z, Wang H, Saji M, Carathers M, Ringel MD, Skipworth RJ, Fearon KC, Hollingsworth MA, Muscarella P, Burghes AH, Rafael-Fortney JA, Guttridge DC: Dystrophin glycoprotein complex dysfunction: a regulatory link between muscular dystrophy and cancer cachexia. Cancer Cell 2005, 8:421-432
88. Martin PT: Dystroglycan glycosylation and its role in matrix binding in skeletal muscle. Glycobiology 2003, 13:55R-66R
89. Michele DE, Barresi R, Kanagawa M, Saito F, Cohn RD, Satz JS, Dollar J, Nishino I, Kelley RI, Somer H, Straub V, Mathews KD, Moore SA, Campbell KP: Post-translational disruption of dystroglycan-ligand interactions in congenital muscular dystrophies. Nature 2002, 418:417-422
90. Rossbach HC, Lacson A, Grana NH, Barbosa JL: Duchenne muscular dystrophy and concomitant metastatic alveolar rhabdomyosarcoma. J Pediatr Hematol Oncol 1999, 21:528-530
91. Jakab Z, Szegedi I, Balogh E, Kiss C, Olah E: Duchenne muscular dystrophy-rhabdomyosarcoma, ichthyosis vulgaris/acute monoblastic leukemia: association of rare genetic disorders and childhood malignant diseases. Med Pediatr Oncol 2002, 39:66-68
92. Langenau DM, Keefe MD, Storer NY, Guyon JR, Kutok JL, Le X, Goessling W, Neuberg DS, Kunkel LM, Zon LI: Effects of RAS on the genesis of embryonal rhabdomyosarcoma. Genes Dev 2007, 21:1382-1395
93. Ren YX, Finckenstein FG, Abdueva DA, Shahbazian V, Chung B, Weinberg KI, Triche TJ, Shimada H, Anderson MJ: Mouse mesenchymal stem cells expressing PAX-FKHR form alveolar rhabdomyosarcomas by cooperating with secondary mutations. Cancer Res 2008, 68:6587-6597
94. Durbeej M, Campbell KP: Muscular dystrophies involving the dystrophin-glycoprotein complex: an overview of current mouse models. Curr Opin Genet Dev 2002, 12:349-361
95. Chamberlain JS, Metzger J, Reyes M, Townsend D, Faulkner JA: Dystrophin-deficient mdx mice display a reduced life span and are susceptible to spontaneous rhabdomyosarcoma. FASEB J 2007, 21:2195-2204
96. Pinto A, Paslawski D, Sarnat HB, Parham DM: Immunohistochemical evaluation of dystrophin expression in small round cell tumors of childhood. Mod Pathol 1993, 6:679-683
97. Howard PL, Dally GY, Ditta SD, Austin RC, Worton RG, Klamut HJ, Ray PN: Dystrophin isoforms DP71 and DP427 have distinct roles in myogenic cells. Muscle Nerve 1999, 22:16-27
98. de Leon MB, Montanez C, Gomez P, Morales-Lazaro SL, Tapia-Ramirez V, Valadez-Graham V, Recillas-Targa F, Yaffe D, Nudel U, Cisneros B: Dystrophin Dp71 expression is down-regulated during myogenesis: role of Sp1 and Sp3 on the Dp71 promoter activity. J Biol Chem 2005, 280:5290-5299
99. de Bernabe DB, Inamori K, Yoshida-Moriguchi T, Weydert CJ, Harper HA, Willer T, Henry MD, Campbell KP: Loss of alpha-dystroglycan laminin binding in epithelium-derived cancers is caused by silencing of LARGE. J Biol Chem 2009, 284:11279-11284
100. Bao X, Kobayashi M, Hatakeyama S, Angata K, Gullberg D, Nakayama J, Fukuda MN, Fukuda M: Tumor suppressor function of laminin-binding alpha-dystroglycan requires a distinct beta3-Nacetylglucosaminyltransferase. Proc Natl Acad Sci USA 2009, 106:12109-12114
101. Nanni P, Nicoletti G, De Giovanni C, Croci S, Astolfi A, Landuzzi L, Di Carlo E, Iezzi M, Musiani P, Lollini PL: Development of rhabdomyosarcoma in HER-2/neu transgenic p53 mutant mice. Cancer Res 2003, 63:2728-2732
102. Tsumura H, Yoshida T, Saito H, Imanaka-Yoshida K, Suzuki N: Cooperation of oncogenic K-ras and p53 deficiency in pleomorphic rhabdomyosarcoma development in adult mice. Oncogene 2006, 25:7673-7679
103. Galindo RL, Allport JA, Olson EN: A drosophila model of the rhabdomyosarcoma initiator PAX7-FKHR. Proc Natl Acad Sci USA 2006, 103:13439-13444
104. Marine JC, Lozano G: Mdm2-mediated ubiquitylation: p53 and beyond, Cell Death Differ 2009, DOI: 10.1038/cdd.2009.68